With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

Ozempic and other drugs like it have been threatening the more traditional weight loss industry since they premiered — and it ...

SkinSpirit, the premier destination for medical aesthetics and leader in Botox and dermal fillers in the nation, is proud to announce that its Chief Medical Officer, Dr. Sachin Shridharani, has been ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth ...

Doha, Qatar: Ebn Sina Medical, a subsidiary of Aamal Company QPSC and a leading supplier of pharmaceutical, and Novo Nordisk ... the availability of Wegovy (Semaglutide 2.4mg) in Qatar.

Novo Nordisk ... could boost Novo Nordisk's stock. For the drugmaker, the key to exploiting the full benefits of this news will be to continue expanding the production of semaglutide, both to ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

Novo Nordisk's oral GLP-1 drug Rybelsus, which also has the same active ingredient semaglutide, is already approved for blood sugar control in adults with diabetes. Novo, Eli Lilly and several ...